In support of this, another specific serotonin receptor inhibitor, ketanserin, targeting the 5-HT2 family (Creed-Carson et al., 2011; Hedner and Persson, 1988), was tested in the primary screen and was not identified as being able to synergise with trametinib to reduce tumour size (File S1). Here, HTR2A is linked to neoplasm.